- US Markets Bracing for Selloff on Dubai Debt Worries
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- US Dollar Falls to 14-Year Low Against the Yen
- UK's Darling to Downgrade 2009 Growth Forecast
- US Companies Already Moving on Curbing Emissions
- Fannie Mae to Tighten Lending Standards: Report
- Investing in Good Karma – and Making a Profit
- Retailers Should Believe in Christmas Miracles
- Bankruptcies Jump, Hitting Highest Level in Four Years
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- Car insurance scofflaws raise health mandate doubt
- Peach farmers block Greek highway
- Perry leads Texas GOP fight against climate bill
- Robotic hamsters are holidays' unlikely new craze
- Bookstore chain Borders UK appoints administrators
- Tommy Hilfiger's estate in Conn. sells for $20M
- Repsol says it will invest $1.5 billion in Bolivia
- Belgium reluctant to renew GM loan offer
- Business software firm RedPrairie files for IPO
Panel likes blood thinner — for some patients
Text Size 
There’s life-saving potential, but don’t give to stroke patients, experts say
SILVER SPRING, Md. - A panel of government health experts says a highly anticipated Eli Lilly blood thinner has lifesaving potential, but should not be given to patients with a history of stroke.
Expert advisers to the Food and Drug Administration say the drug's labeling should alert doctors that stroke patients face a high risk of suffering another stroke if they take the medication.
The panel will vote later today on whether to recommend approval of the experimental drug. The FDA is not required to follow the group's recommendations, though it usually does.
Indianapolis-based Eli Lilly has asked the Food and Drug Administration to approve its highly anticipated drug to prevent dangerous blood clots in patients with acute heart problems.
Click for related content
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Print
Email
- What you need to know.
- Ever wished your cab driver would stop nattering and just get to where you're going? Well that moment is near(er).
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
Data is a real-time snapshot *Data is delayed at least 15 minutes